Equities research analysts expect Nevro Corp. (NYSE:NVRO) to post earnings per share of ($0.23) for the current quarter, Zacks reports. Four analysts have made estimates for Nevro Corp.’s earnings. The lowest EPS estimate is ($0.38) and the highest is ($0.04). Nevro Corp. reported earnings per share of ($0.14) in the same quarter last year, which suggests a negative year-over-year growth rate of 64.3%. The company is expected to announce its next quarterly earnings report on Monday, November 6th.

According to Zacks, analysts expect that Nevro Corp. will report full-year earnings of ($1.20) per share for the current year, with EPS estimates ranging from ($1.43) to ($0.87). For the next year, analysts forecast that the business will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.97) to $1.06. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Nevro Corp..

Nevro Corp. (NYSE:NVRO) last posted its quarterly earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.11). The business had revenue of $78.02 million during the quarter, compared to analysts’ expectations of $77.75 million. Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.31) earnings per share.

Several equities analysts have weighed in on NVRO shares. Zacks Investment Research lowered shares of Nevro Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. BMO Capital Markets reaffirmed a “buy” rating and issued a $106.00 price objective on shares of Nevro Corp. in a research note on Friday, September 1st. BidaskClub raised shares of Nevro Corp. from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. J P Morgan Chase & Co reissued an “overweight” rating and set a $102.00 target price on shares of Nevro Corp. in a research report on Monday, July 3rd. Finally, Northland Securities set a $96.00 target price on shares of Nevro Corp. and gave the stock a “buy” rating in a research report on Thursday, June 15th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $101.25.

In other Nevro Corp. news, Director Michael F. Demane sold 5,000 shares of the firm’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $93.50, for a total value of $467,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $82.31, for a total transaction of $576,170.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 290,907 shares of company stock valued at $24,670,065. Corporate insiders own 12.10% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Roosevelt Investment Group Inc. acquired a new stake in Nevro Corp. during the 2nd quarter worth approximately $3,958,000. State Street Corp lifted its position in shares of Nevro Corp. by 4.9% during the 1st quarter. State Street Corp now owns 461,309 shares of the medical equipment provider’s stock valued at $43,222,000 after acquiring an additional 21,558 shares during the period. Gotham Asset Management LLC acquired a new position in shares of Nevro Corp. during the 1st quarter valued at $931,000. BlueCrest Capital Management Ltd acquired a new position in shares of Nevro Corp. during the 1st quarter valued at $1,040,000. Finally, Vanguard Group Inc. lifted its position in shares of Nevro Corp. by 5.4% during the 1st quarter. Vanguard Group Inc. now owns 1,934,593 shares of the medical equipment provider’s stock valued at $181,271,000 after acquiring an additional 98,555 shares during the period.

Nevro Corp. (NYSE:NVRO) traded up 0.67% during trading on Wednesday, hitting $92.82. The stock had a trading volume of 183,146 shares. The company’s market cap is $2.73 billion. Nevro Corp. has a one year low of $65.82 and a one year high of $102.26. The firm has a 50 day moving average of $88.43 and a 200-day moving average of $83.72.

COPYRIGHT VIOLATION WARNING: “-$0.23 EPS Expected for Nevro Corp. (NVRO) This Quarter” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/0-23-eps-expected-for-nevro-corp-nvro-this-quarter.html.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Get a free copy of the Zacks research report on Nevro Corp. (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.